Investigation Launched on TEVA. The Competition Board (Board) concluded the preliminary inquiry conducted in order to determine if Teva İlaçları San. ve Tic. AŞ (TEVA) violated Article 6 of the Act no 4054 on the Protection of Competition (Act no 4054) by engaging in conduct intended to restrict competition from generic medicines, through the strategic use of divisional patent procedures and creation of a misleading impression before healthcare authorities regarding the efficacy and safety of competing products. The Board launched an investigation on the economic unity composed of Teva İlaçları San. ve Tic. AŞ, Teva Pharmaceuticals Europe B.V. and Teva Pharmaceutical Industries Ltd with its decision dated 06.08.2026 and numbered 26-28/804-M, in order to determine if the aforementioned conduct violated Article 6 of the Act no 4054. Various practices of TEVA that may have been aimed at making it more difficult for competitors to enter the market are the subject matter of the investigation. TEVA is a pharmaceutical company operating at the global scale, which has self-developed patented products in various branches of medicine, such as neurology and immunology. The investigation will assess whether TEVA’s divisional patent applications relating to the manufacturing process and dosage regimen following the expiry of the protection period of its basic molecule patent, together with withdrawal practices associated with these patents, are capable of restricting competition from generic medicines.
